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A B S T R A C T
Objective: To analyze the change in health-related quality-of-life (HRQoL) in patients with
Parkinson’s disease (PD) and to identify different classes of HRQoL decline.
Methods: A longitudinal cohort study was performed to assess clinical parameters (unified
PD rating scale, Beck Depression Inventory) and HRQoL data (EuroQol, Parkinson’s Disease
Questionnaire [PDQ]-39) at baseline, 3, 6, 12, 24, and 36 months. A total of 145 patients with
PD were consecutively recruited in the county of Northern Hessia, Germany, between Jan-
uary and June 2000. A latent growth mixture model was applied to analyse the heterogeneity
in HRQoL trajectories.
Results: We successfully applied latent mixture growth modeling in order to identify dif-
ferent classes of HRQoL trajectories in PD. Three growth models were developed and each
resulted in a four-class model of distinct patterns using the generic EuroQol instruments’
outcomes (EuroQol-5 Dimensions and visual analogue scale) and the disease-specific PDQ-
39. The four classes were defined by individual trajectory characteristics. Classes one and
two represented trajectories with moderate declines over 36 months, but with different
initial intercepts. Class three consisted mainly of patients who passed away during the
observation period and therefore had a large HRQoL decline. Class four was characterized by
a low level of HRQoL at baseline and a significant subsequent decline.
Conclusions: The findings provide a more elaborate understanding of the variability in HRQoL
reduction in PD over time. The classification of different HRQoL subgroups may help to explain
the response of PD patients to the natural history of the disease. Future research will enable the
identification of HRQoL responder subgroups on different treatment regimens.
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Health-related quality-of-life (HRQoL) has become a key
concept in patient-relevant outcomes research. In the ab-
sence of biomarkers adequately describing the progression
of Parkinson’s disease (PD), patient-relevant outcomes are
required to ensure that treatments in fact provide substan-
tial benefits and do not only represent physiological surro-
gates without any influence on the patients’ well-being. Dis-
ease-specific and generic HRQoL instruments have been
developed and used to measure the subjective perception of
disease, as well as the improvement or deterioration caused
by therapeutic interventions [1– 4]. In cancer for instance,
RQoL measures are already tested for their prognostic
alue (e.g. [5,6]).
For PD, several disease-specific instruments are avail-
ble and have already been applied in randomized con-
rolled trials as a response measure to therapy – the Parkin-
on’s disease quality-of-life questionnaire (PDQL) [7] and
he 39-item Parkinson’s disease Questionnaire (PDQ-39) [8 –
1].
The impairment of HRQoL by PD is well described in the
iterature. The progressive and chronic nature of PD sug-
ests that HRQoL will decline during the course of the dis-
ase [2]. Several studies have reported an independent as-
ociation of decreased HRQoL and more severe (Hoehn and
ahr) disease stages [12]. Furthermore, motor complica-
ions such as motor fluctuations, dyskinesias, dystonia, and
reezing as well as non-motor complications such as de-
entia, depression, or psychosis considerably decrease
RQoL [13]. Because HRQoL is a concept that is based on the
ubjective impression of the patient, it seems probable that
eterminants of self-perception and differences in coping
trategies of the patients, in combination with their clinical
nd socio-demographic characteristics, influence and de-
ermine the change in self-reported HRQoL [14]. Given the
arge number of influences on HRQoL that may vary be-
ween individuals and within individuals over time, much
eterogeneity of HRQoL trajectories in patients with PD can
e expected.
When revisiting data from one of our own studies, we
ound that the individual trajectories for EQ-5D and PDQ-39
ndeed showed remarkable heterogeneity for the 145 patients
ollowed-up for 36 months. The subjects had an almost con-
tant or decreasing quality of life during follow-up (Fig. 1 [13]).
In contrast with conventional methods that are used to
nalyze longitudinal repeated measures, such as analysis of
ariance, the latent mixture growth model provides a tool for
odeling heterogeneity in the individual trajectories across
ime. The traditional analysis of variance approach is limited
y its assumptions regarding missing data and the variance–
ovariance structure over time. In the analysis of variance
ith repeated measures, it is assumed that the variance and
ovariance of the outcome variable are equal over time. This
ssumption failed for our previous data [13] and the tradi-
ional analysis of variance model did not fit the data. The ap-
lication of growth models (mixed effect models) does not
ave this stringent assumption about the covariance matrixver time, and provides a flexible approach for longitudinal
ata modeling. The inclusion of latent variables into the
rowth model allows for the modeling of heterogeneity in in-
ividual trajectories over time. The estimated latent classes
re characterized by the homogeneous characteristics of sub-
ects within classes and distinctive characteristics between
lasses. The latent mixture growth model can be interpreted
s a combination of mixed-effects modeling and cluster anal-
sis [15,16].
In the current study, we used such models to examine lon-
itudinal changes in HRQoL using generic as well as disease-
pecific instruments. Our approach allows for the prediction
f distinct classes of HRQoL trajectories based on changes over
ime and the estimation of the most likely class membership
f each individual.
Fig. 1 – Unadjusted single mean growth curve for EQ-5D
index (a) and PDQ-39 (b) over 36 months. Solid line:
estimated unadjusted mean growth curve; dashed line:
individual trajectories; T0: baseline examination; T1:
3-month examination; T2: 6-month examination; T3: 12-
month examination; T4: 24-month examination; T5: 36-
month examination.
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Study design
A total of 145 patients (97 male; 48 female) with idiopathic PD
were consecutively recruited in the county of North Hessia,
Germany, between January and June 2000. A detailed de-
scription of the study was reported recently [13]. Briefly,
study sites included the Outpatient Department for Move-
ment Disorders, Department of Neurology, Philipps-Univer-
sity Marburg (n29), the Paracelsus Elena Clinic, Kassel
(n31), two office-based neurologists (n40), and general
practitioners (n45). Each patient received a structured as-
sessment of parkinsonian signs and neurological symptoms
(such as freezing and gait disturbances) conducted by a move-
ment disorders specialist and their medical history was doc-
umented. Idiopathic Parkinson’s disease was diagnosed ac-
cording to the clinical criteria of the U.K. Parkinson’s disease
Society Brain Bank [17]. Patients were examined at baseline
(T0), at 3 months (T1), 6 months (T2), 12 months (T3), 24
months (T4), and 36 months (T5). The study was approved by
the local ethics committee and all participants gave informed
consent.
Evaluation of HRQoL
Patient-reported HRQoL was measured by the generic EuroQol
instrument [18] and the Parkinson-specific questionnaire
PDQ-39 [19,20]. The EuroQol is widely used in clinical and eco-
nomic evaluations. It covers the domains of mobility, self-
Fig. 2 – Hypothesized growth model diagram for HRQol over
observed variables; circles: latent variables; directed lines: regrescare, usual activities, pain/discomfort, and anxiety/depres-
sion. A single utility index score (EQ-5D index) is calculated by
applying a scoring algorithm [21]. The second part of the
EuroQol is a visual analogue scale (EQ-VAS) that is used to
mark the patient’s current health status on a scale ranging
from 0 to 100. The PDQ-39 is a widely used, reliable, and valid
PD-specific quality of life instrument. Thirty-nine items ex-
amine eight dimensions (“mobility,” “activities of daily living,”
“emotional well-being,” “stigma,” “social support,” “cogni-
tion,” “communication,” and “bodily discomfort”) and provide
a composite score. Higher values of the PDQ-39 sum score
indicate a lower quality of life.
Disease severity
The disease severity in each patient was examined using the
Hoehn and Yahr Scale [22] and the unified Parkinson’s disease
Rating Scale (UPDRS) parts II–IV [23]. UPDRS II assesses activ-
ities of daily living (e.g. speech, falling, freezing), UPDRS III
comprises a motor examination, including tremor, gait or ri-
gidity, and UPDRS IV describes complications of therapy by
means of a) dyskinesias; b) clinical fluctuations; and c) other
complications.
Depressive symptoms were assessed by the Beck Depres-
sion Inventory (BDI) [24]. This is a reliable and valid measure
for use in patients with PD [25]. Higher scores indicate in-
creased depressive symptoms. Cognitive impairment was
measured using the Mini Mental State Examination (MMSE). A
summary-score of less than 19 was rated as probable cognitive
impairment [26].
onths in patients with Parkinson’s disease. Square boxes:36 m
sion equation.
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The analysis was based on 145 patients who participated at
baseline (BL). At the 36-month assessment, 23 patients were
lost to follow-up because of death, individual reasons (n22),
a too-complex study protocol (n8), admission into a nursing
home (n1) and other reasons (n3), resulting in a sample of
88 patients.
The missing values were estimated by full-information
maximum-likelihood estimation assuming missing at ran-
dom, which is a widely accepted method for handling miss-
ing data [27,28]. Twenty-three patients passed away during
the 36-month follow-up, and the missing outcome values
for these patients were imputed as zero (EuroQoL) or worst
possible (PDQ-39), which is, according to the instruments
used, the value for the health state ‘death’ [18,19]. In addi-
tion, the last observations carried forward (LOCF) method
and multiple imputation by chained equations (MICE) [29]
were used to assess the sensitivity of the latent growth mix-
ture model with respect to missing data modeling. The pre-
dictor variables HRQoL at previous assessment (e.g., BL is
the previous assessment to 6-month follow-up), UPDRS III,
UPDRS IV, BDI, and gender were applied in the MICE ap-
proach.
We analyzed each HRQoL measure (EQ-5D, EQ-VAS, and
Table 1 – Clinical characteristics of the study sample.
Baseline
N (%)/mean  SD N
No. of patients 145
Age 67.3  9.6
Female 48 (33.1%)
Duration of disease 9.3 7.4
Hoehn and Yahr (HY)* 3 (2–4)
HY I 19 (13.1%)
HY II 43 (29.7%)
HY III 44 (30.3%)
HY IV 25 (17.2%)
HY V 14 (9.7%)
UPDRS
Sum score† 48.1  33.3
UPDRS II 12.9  10.4
UPDRS III 31.2  21.6
UPDRS IVa 1.3  2.3
UPDRS IVb 1.7  2.0
UPDRS IVc 0.9  0.9
MMSE
15 8 (5.6%)
15–19 3 (2.1%)
20–24 24 (16.7%)
25–27 35 (24.3%)
28–30 74 (51.4%)
BDI
Normal 73 (55.7%)
Moderate depression 41 (31.3%)
Clinically relevant depression 17 (13.0%)
BDI, Beck Depression Inventory; MMSE, Mini Mental State Examina
Scale.
* Hoehn and Yahr reported by median (interquartile range).
† UPDRS Sum Score: Sum of UPDRS II, UPDRS III and UPDRS IV.PDQ-39) with a separate latent growth mixture model [16] toidentify distinct groups with a common pattern of HRQoL tra-
jectories. The growth factor (slope) was modeled using a
piecewise linear function to capture different growth rates for
the time intervals BL to 6 months, 6 months to 24 months, and
24 months to 36 months. The intercept parameter (estimated
baseline value of the outcome) and the probability of class
membership were adjusted for gender and baseline values of
UPDRS III, UPDRS IV, and BDI scores in the final models (Fig. 2).
A detailed mathematical presentation of latent growth mix-
ture modeling is provided elsewhere [16,30].
In the first step, a single-class model (classical analysis)
was specified to investigate the overall growth function for
quality of life over time. A mixture growth model with K latent
classes (K2,3, . . .) was formulated to study possible sub-
groups of patients characterized by class-specific intercepts
and slopes in the second step. The number of classes K was
chosen by considering the bootstrap likelihood ratio test
(BLRT) [31], which provides a consistently performing model
test.
The standard errors of the model parameters (intercept
and slope estimates) were estimated by applying a sandwich
estimator [32] that took into account the clustered sampling
design (patients were clustered within study centers). The pa-
rameters were estimated by maximum likelihood. Multiple
sets of starting values were applied to avoid local solutions in
month 24 month 36 month
mean  SD N (%)/mean  SD N (%)/mean  SD
128 112 88
.8  43.9 75.7  63.2 89.2  69.3
.1  13.8 20.9  16.8 22.6  17.8
.7  26.5 40.3  34.3 46.7  36.7
.7  3.3 3.6  5.0 4.7  5.7
.2  2.5 2.0  2.5 2.2  2.9
.0  0.9 1.5  1.0 1.4  1.1
(14.2%) 25 (22.3%) 25 (22.0%)
2 (1.8%) 2 (1.8%)
(11.2%) 10 (8.9%) 5 (4.4%)
(15.7%) 23 (20.5%) 17 (15.0%)
(59.0%) 52 (46.4%) 39 (34.3%)
(61.0%) 40 (48.8%) 30 (41.7%)
(26.0%) 16 (19.5%) 14 (19.4%)
(13.0%) 26 (31.7%) 28 (38.9%)
SD, standard deviation; UPDRS, Unified Parkinson’s Disease Rating12
(%)/
59
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1
2
1
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333V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 2 9 – 3 3 8estimated for the EQ-5D, EQ-VAS, and PDQ-39 in MPLUS 5.21
[33]. Characterization of the estimated latent classes and sub-
sequent analysis were conducted using STATA 10.2 (Stata
Corp., College Station, Texas, USA) [34].
In more detail, patient’s clinical characteristics at baseline
were compared across the estimated latent classes by linear
regression models for dimensional variables (age, age at
symptom onset, duration of disease, Hoehn & Yahr, UPDRS,
BDI, MMSE) and logistic regression models for categorical vari-
ables (gender, gait disturbances, dyskinesias, falls, fluctua-
tions).
Results
The mean age of the sample of 145 patients was 67.3 years old
(95% CI: 65.7–68.8) with 48 females (33.1%). The mean age of PD
onset was 57.6 years old (95% CI: 55.6–59.6) and the mean
duration of disease was 9.3 years (95% CI: 8.0–10.5). According
to the Hoehn and Yahr scale, 42.8% were stage I/II, 30.3% were
stage III, and 26.9% were stage IV/V at baseline. The summary
UPDRS (II–IV) score was 48.1 (95% CI: 42.6–53.5). The clinical
characteristics of the study sample are reported in Table 1.
Fifty-seven subjects were lost to follow-up by death
N23) and other reasons for drop-out (N34). Baseline
characteristics by drop-out status are reported in Table 1,
which can be viewed at: doi:10.1016/j.jval.2010.10.005. Sub-
ects lost to follow-up by other reasons are comparable to
ubjects followed by the 36-month study period in baseline
haracteristics. Subjects who died during the study period
re characterized by longer duration of Parkinson’s disease,
igher UPDRS scores, and increased stages in the Hoehn
Table 2 – Fit indices for the general growth mixture model
baseline value and probability of class membership.
Model No. classes logL *Par
EQ-5
1 1 136 18
2 2 239 27
3 3 269 36
4 4 305 45
5 5 327 54
EQ-
6 1 3047 18
7 2 2946 27
8 3 2897 36
9 4 2874 45
10† 5 2855 54
P
11 1 2926 18
12 2 2809 27
13† 3 2764 36
14 4 2695 45
15 5 2671 54
aBIC, sample-size adjusted Bayesian information criteria; BDI, Bec
strapped likelihood ratio test; UPDRS: Unified Parkinson’s Disease Ra
* Number of free model parameters.
† The model did not converge normally.nd Yahr scale.Figure 1 depicts the unadjusted result of an ordinary
rowth model of the EQ-5D index as a single mean growth
urve. The estimated mean of the EQ-5D index was 0.85 (95%
I: 0.79–0.89) adjusted for UPDRS III, UPDRS IV, and BDI at
aseline. It showed a nearly constant course from T0 to T2
0.01, 95% CI: 0.08–0.03) and a significant decrease in
uality of life from T2 to T5 (T2–T4: 0.06, 95% CI: 0.09–
0.03 and T4–T5: 0.05, 95% CI: 0.09–0.01). Obviously,
he individual trajectories are very heterogeneous. There are
atients with growth rates that differ substantially from the
stimated average trajectory. Thus, a latent growth curve
odel was applied to model this heterogeneity in the data.
The fit for the two-class, three-class, four-class, and five-
lass models with UPDRS III, UPDRS IV, BDI, and gender-ad-
usted probabilities of class membership and intercept param-
ters is shown in Table 2. The four-class model was regarded
s the most appropriate to describe the heterogeneity based
n a) the comparison of fit indices (Table 2); b) the visual com-
arison of individual trajectories with the estimated unad-
usted mean growth curve within class (Fig. 3); and c) the number
f patients within a class (Table 3). For example, the five-class
odel does not add information compared to the four-class
odel for the EQ-5D index (Table 2). It simply divides class 4 into
wo subclasses.
The parameter estimates of the growth curves for the four
atent classes of the EQ-5D index, EQ-VAS and PDQ-39 sum
core are reported in Table 3 with the baseline value and prob-
bility of class membership adjusted for UPDRS III, UPDRS IV,
nd BDI. The first latent class included patients with a high
Q-5D index at baseline (0.99; 95% CI: 0.97–1.00) and a non-
significant decrease over time. There was a related pattern for
the trajectories in class 2 except that the EQ-5D index at base-
BDI, UPDRS III+IV, and gender-adjusted estimates of the
BIC aBIC Entropy BLRT
ex
182 239
343 429 0.866 0.000
359 473 0.783 0.000
386 529 0.890 0.000
385 555 0.862 0.667
AS
6183 6126
6027 5941 0.855 0.000
5973 5860 0.831 0.000
5971 5829 0.858 0.043
5978 5807 0.881 0.667
5942 5885
5752 5667 0.848 0.000
5706 5592 0.872 0.000
5615 5472 0.866 0.013
5611 5440 0.908 1.000
ression Inventory; BIC, Bayesian information criteria; BLRT, boot-
cale.with
D ind
5D V
DQ-39
k Dep
ting Sline was lower compared to class 1 (0.79; 95% CI: 0.75–0.82).
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334 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 2 9 – 3 3 8In contrast, patients in classes 3 and 4 had a high HRQoL (class
3: 0.88; 95% CI: 0.82–0.95) or a moderate HRQoL (class 4:
0.66; 95% CI: 0.60–0.71) at baseline and a significant de-
rease over time (Fig. 3).
The baseline correlates of the estimated four classes for the
Q-5D index are reported in Table 4. Patients in class 1 were
ess impaired according to clinical characteristics (UPDRS (II–
V); sum score27.9, 95% CI: 20.7–35.1; UPDRS III20.2, 95% CI:
5.0–25.3; 60.7% in Hoehn and Yahr stages I and II) and had a
hort disease duration (mean7.0 years, 95% CI: 5.4–8.6) com-
ared with the other classes. Classes 2 and 3 are comparable
y clinical characteristics and HRQoL at baseline, whereas al-
ost all patients in class 3 (N7, 88%) passed away during the
ollow-up period resulting in a significant decrease in HRQoL
ver time. Latent classes 3 and 4 included patients who passed
way during follow-up. The two classes differed in respect to
he time of death and the mean HRQoL at baseline. Class 3
ncluded cases of death that occurred in later follow-up waves
ith a high HRQoL at baseline, whereas class 4 included cases
hat passed away in earlier stages of follow-up. Classes 2 and
were comparable in baseline clinical and socio-demographic
arameters. Detailed analyses are shown in Table 4, which
resents the correlates for the estimated four-class model.
atients in class 4 are characterized by a high UPDRS (II–IV)
um score (mean84.8, 95% CI: 73.4–96.2), a long disease du-
ation (mean  14.4, 95% CI: 11.4–17.4) and were older
mean73.9, 95% CI: 70.2–77.5).
We also studied the EQ-VAS and the PD-specific quality of
ife measure PDQ-39. In both cases, the general growth mix-
ure model also resulted in a four-class model (Table 2). The
attern of EQ-VAS and PDQ-39 was comparable to the EQ-5D
ndex within latent classes (Table 3). The absolute agreement
Table 3 – Parameter estimates for growth functions of the
measures (BDI, UPDRS III+IV, and gender-adjusted estimat
Class 1 C
Beta* 95% CI Beta*
EQ-5D index
Patients (n) 28
Mean value at baseline 0.99† 0.97 – 1.00 0.79†
 T0–T2 0.02 0.05 – 0.02 0.02†
 T2–T4 0.02 0.05 – 0.02 0.01
 T4–T5 0.08 0.17 – 0.01 0.02
EQ-5D VAS
Patients (n) 54
Mean value at baseline 79.24† 73.21 – 85.27 61.18†
 T0–T2 0.05 1.95 – 1.85 0.14
 T2–T4 0.49 2.68 – 1.70 0.68
 T4–T5 0.15 4.08 – 4.37 2.70
PDQ-39
Patients (n) 59
Mean value at baseline 3.29† 0.19 – 6.40 16.43†
 T0–T2 2.03† 3.09 – 0.97 1.53
 T2–T4 2.16† 0.21 – 4.10 3.27†
 T4–T5 0.68 4.68 – 3.32 0.06
BDI, Beck Depression Inventory; CI, confidence interval; UPDRS, Unifi
* BDI, UPDRS IIIIV and gender adjusted estimates of the baseline v
† Coefficients are significant on the 5% level.etween the EQ-5D index and EQ-VAS latent classes was 78.9%,esulting in a kappa of 0.6 (P  0.001). More than 50% (56.3%) of
he subjects were classified in the same latent class of the EQ-5D
ndex and PDQ-39, yielding a kappa of 0.4 (P 0.001).
Discussion
Latent longitudinal models of growth are increasingly being
used in the analysis of patient-reported outcomes in neuro-
logical diseases, e.g., in dementia [35,36] and multiple sclero-
sis [37].
Our study is the first to apply the growth mixture modeling
technique to longitudinal changes in HRQoL in patients with
PD. We successfully determined four subgroups of patients
that differed in their course of HRQoL across a 36-month study
period. Interestingly, as outlined in an earlier communication,
patients do not deteriorate in the first 6 months according to
the PDQ-39 instrument and the EuroQol measures [13]. The
trajectories in classes 1 and 2 did not show a considerable
decline over the 3 years of the study, but had different initial
intercepts. In comparison, patients in classes 3 and 4 experi-
enced a substantial decrease in HRQoL following a lower ini-
tial status compared to classes 1 and 2. As expected, members
of latent class 4, who showed the most severe trajectory, had a
significantly longer duration of disease and higher UPDRS val-
ues. Nearly all patients (90%) in class 3 passed away during the
36-month study, having a moderate quality of life at baseline
followed by a large decline. Patients in class 4 were older and
were characterized by a lower level of HRQoL and a low level of
clinical parameters at baseline. Altogether, PD patients were
split into patients with a decline in HRQoL (latent classes 3 and
4) and those with a stable HRQoL (latent classes 1 and 2) over
class general growth mixture model for quality of life
f the baseline value and probability of class membership).
2 Class 3 Class 4
5% CI Beta* 95% CI Beta* 95% CI
8 30
5 – 0.82 0.88† 0.82 – 0.95 0.66† 0.60 – 0.71
0 – 0.03 0.02 0.04 – 0.09 0.03 0.07 – 0.02
4 – 0.01 0.29† 0.38 – 0.20 0.13† 0.17 – 0.09
6 – 0.03 0.05 0.15 – 0.04 0.07 0.17 – 0.03
6 24
7 – 69.69 81.78† 73.53 – 90.02 56.04† 46.92 – 65.16
2 – 2.99 0.90 3.44 – 5.24 3.20 8.42 – 2.03
8 – 3.43 19.18† 30.08 – 8.29 20.61† 25.27 – 15.94
6 – 4.55 29.73† 51.04 – 8.41 1.20 2.94 – 5.33
19 13
7 – 20.70 8.80† 4.58 – 13.02 23.63† 12.40 – 34.86
2 – 0.16 1.80 3.90 – 0.30 14.88† 3.32 – 26.44
2 – 6.12 30.91† 23.16 – 38.66 10.52† 0.55 – 20.49
5 – 5.24 7.48 4.70 – 19.67 6.01 12.08 – 0.06
rkinson’s Disease Rating Scale; VAS, visual analogue scale.
nd probability of class membership.four-
es o
lass
9
79
0.7
0.0
0.0
0.0
61
52.6
2.7
2.0
9.9
54
12.1
3.2
0.4
5.3
ed Pa
alue atime.
335V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 2 9 – 3 3 8We developed three separate models for the HRQoL mea-
sures assessed in this study: 1) the EQ-5D index score; 2) the
EQ-VAS score; and 3) the PDQ-39. Although all three models
gave four latent classes, this fact must be interpreted with
caution. Due to the absolute agreement between these mea-
sures in the assignment of class membership, we reason that
there is also a high level of agreement regarding what is mea-
sured in terms of HRQoL and responsiveness to PD progres-
sion. However, the psychometric characteristics differ com-
pletely between the three scales [2]. Thus, a higher level of
agreement would not necessarily be expected even if the sta-
tistical power were increased by larger sample sizes and the
inclusion of more covariates. Latent growth modeling should
be considered as an appropriate method when comparing the
Fig. 3 – Model estimated unadjusted growth curves for EQ-5
general growth mixture solution. Solid line: estimated unad
T0: baseline examination; T1: 3-month examination; T2: 6-m
examination; T5: 36-month examination.responsiveness of PD scales to change over time.The application of growth mixture modeling allows for
considering the investigated outcome over time and for
modeling unobserved heterogeneity among patients rather
than considering a single growth rate. This method can de-
tect changes in outcome measures not only in a group of
patients, but also individual differences in changes in out-
come rates among group members. The mixture model ap-
proach considers the fact that individuals within a certain
population start and end at different points with regard to
their HRQoL measures over the longitudinal study period
[38]. The growth mixture models are used to detect sub-
groups of individuals by usage of a latent class membership
variable [29]. In other words, growth mixture modeling in-
vestigates whether there is enough homogeneity in changes
ex (A) and PDQ-39 (A) over 36 months for the four-class
d mean growth curve; dashed line: individual trajectories;
h examination; T3: 12-month examination; T4: 24-monthD ind
juste
ontover time to allow the separation of classes of individuals
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336 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 2 9 – 3 3 8who differ with regard to their baseline measures and rates
of change over time.
Although we carefully designed the analyses, there are sev-
eral limitations to this study. The patients were consecutively
enrolled in the participating study centers without a random-
ization protocol. However, this convenience sample could be
considered to be representative for patients suffering from
Parkinson’s disease in the region North Hessia, Germany. Fur-
thermore, we present a latent general growth mixture model
for HRQoL in a sample of 145 patients with Parkinson’s dis-
ease. The sample size might limit our approach as follows:
1) the baseline value (intercept) of HRQoL was adjusted for BDI,
UPDRS IIIIV, and gender (Fig. 2). With a larger sample size,
additional covariates could have extended the modeling
framework in terms of its predictive power from the intercept
towards class membership. 2) It would have been possible to
include time-varying covariates, since the change in HRQoL
over time (slope) depends on the course of disease severity.
Modeling was also conducted using time varying covariates
BDI and UPDRS IIIIV, but the algorithm for parameter esti-
mation did not converge normally; and 3) the sample was
characterized by a clustered design in terms of different re-
cruitment settings. The introduction of a multilevel growth
model would have provided an alternative for estimating
standard errors accounting for the patients’ characteristics
within study centers. This approach would also require a
larger sample size. Thus, we conclude that a larger sample size
would be necessary to obtain stable parameter estimates for a
more complex model with time-varying covariates. Neverthe-
Table 4 – Baseline correlates of EQ-5D index latent class m
of the baseline value and probability of class membership)
Class 1 (reference) Class 2
Mean  SD/(range) Mean  SD/(range) OR/MD (95% C
Female N (%) 16 (57.1%) 23 (29.1%) 0.3* (0.1 – 0.8)
Age 64.0  9.4/(42 – 76) 66.1  8.8/(37 – 79) 2.1 (1.9 – 6.
Age at symptom onset 57.1 10.8/(33 – 70) 57.7  13.1/(14 – 76) 0.6 (4.3 – 5.
Duration of disease 7.0 4.2/(1 – 16) 8.5  7.6/(1 – 36) 1.5 (0.8 – 3.
Hoehn and Yahr, median 2/(1 – 3) 2/(1 – 5) 0.2 (0.1 – 0.
Dyskinesias, N (%) 24 (85.7%) 55 (69.6%) 0.4 (0.1 – 1.2)
Gait disturbances, N (%) 16 (57.1%) 31 (39.2%) 0.5 (0.2 – 1.2)
Falls, N (%) 25 (89.3%) 51 (64.6%) 0.2* (0.1 – 0.8)
Fluctuations, N(%) 20 (71.4%) 48 (60.8%) 0.6 (0.2 – 1.6)
BDI 11.5  8.3/(0 – 27) 9.8  6.3/(0 – 31) 1.7 (5.2 – 1.
UPDRS
Sum score† 27.9  18.6/(6 – 79) 41.7  28.2/(8 – 145) 13.8* (4.4 – 23.1
UPDRS II 5.6  4.4/(0 – 19) 10.8 8.2/(0 – 38) 5.2* (2.7 – 7.6)
UPDRS III 20.2  13.2/(1 – 57) 27.1  18.9/(5 – 100) 7.0* (0.5 – 13.5
UPDRS IV 2.1  2.5/(0 – 9) 3.7  4.0/(0 – 15) 1.6* (0.3 – 2.9)
UPDRS Iva 0.6  1.4/(0 – 5) 1.5  2.6/(0 – 10) 0.9* (0.2 – 1.7)
UPDRS Ivb 0.9  1.1/(0 – 3) 1.4  1.8/(0 – 7) 0.6 (0.0 – 1.1)
UPDRS Ivc 0.7  0.7/(0 – 2) 0.8  0.9/(0 – 3) 0.1 (0.2 – 0.
MMSE 27.4  2.5/(21 – 30) 27.1  2.8/(15 – 30) 0.3 (1.4 – 0.
Cumulative mortality (N)
3 months 0 0
6 months 0 0
12 months 0 0
24 months 0 0
36 months 1 0
Dyskinesias, gait disturbances, falls and fluctuations were recorded by UPDRS IV
BDI, Beck Depression Inventory; CI, confidence interval; MD  mean differen
categorical data; UPDRS Unified Parkinson’s Disease Rating Scale.
 Beta coefficients are significant on the 5% level.
† UPDRS Sum Score: Sum of UPDRS II, UPDRS III and UPDRS IV.less, the sample size of this study was appropriate for robust cparameter estimates and convergence of the estimation algo-
rithm when using a growth mixture model with a small num-
ber of covariates [39].
To test the robustness of our assumption about using the
orst possible score in EuroQol and PDQ-39 for the 23 patients
ho passed away, we applied the last observation carried for-
ard method (LOCF) and multiple imputations by chained
quations (MICE). The latent growth mixture models for the
Q-5D index, EQ VAS, and PDQ-39 in the LOCF data resulted in
three-class solution based on fit indices. The main difference
as the collapsing of class 3 and 4 into a single class compared
o the models reported in Table 3 (see Appendix Table 2 at
oi:10.1016/j.jval.2010.10.005.
This fact could be caused by the LOCF approach. The with-
n-subject variance is reduced for patients with missing val-
es imputed by the LOCF method, resulting in a constant
ourse of HRQoL across follow-up for these patients. In con-
rast, the course of HRQoL across time is estimated in the
ther missing value models applied in this study. There are
emarkable differences in the clinical characteristics at base-
ine between classes 3 and 4 of the model described in Table 3.
atients of the two classes differ significantly with respect to
ime of death, age, duration of disease and disease severity
Hoehn and Yahr, UPDRS). Application of the MICE approach
or estimating the missing values resulted in a four-class so-
ution comparable to the final model reported in Table 3.
We cannot rule out the possibility that other covariates
hat were not included in the model may have influenced the
RQoL trajectories. In particular, non-motor symptoms – psy-
ership (BDI, UPDRS III+IV, and gender-adjusted estimates
Class 3 Class 4
Mean SD/(range) OR/MD (95% CI) Mean SD/(range) OR/MD (95% CI)
2 (25.0%) 0.3 (0.0 – 1.5) 7 (23.3%) 0.2* (0.1 – 0.7)
5.8  7.8/(54 – 74) 1.8 (4.5 – 8.0) 73.9  9.8/(49 – 94) 9.9* (4.9 – 14.9)
7.9  8.5/(46 – 72) 0.8 (6.1 – 7.7) 57.6  11.4/(34 – 76) 0.5 (5.4 – 6.4)
7.9 6.8/(1 – 21) 0.9 (3.9 – 5.7) 14.4  7.6/(3 – 31) 7.5* (4.2 – 10.7)
3/(2 – 4) 0.5 (0.1 – 1.0) 4/(2 – 5) 1.8* (1.5 – 2.2)
7 (87.5%) 1.2 (0.1 – 12.3) 19 (63.3%) 0.3* (0.1 – 1.1)
1 (12.5%) 0.1* (0.0 – 1.0) 1 (3.3%) 0.0* (0.0 – 0.2)
6 (75.0%) 0.4 (0.0 – 2.7) 6 (20.0%) 0.0* (0.0 – 0.1)
6 (75.0%) 1.2 (0.2 – 7.3) 7 (23.3%) 0.1* (0.0 – 0.4)
2.5 8.0/(3 – 26) 1.0 (5.2 – 7.1) 10.4  5.9/(3 – 23) 1.2 (5.2 – 2.9)
4.1 29.4/(11 – 101) 16.2 (4.5 – 36.8) 84.8  30.5/(28 – 155) 56.9* (43.9 – 69.9)
1.9 9.2/(2 – 28) 6.2 (0.1 – 12.6) 25.3 9.9/(8 – 46) 19.7* (15.8 – 23.6)
9.3 20.8/(8 – 75) 9.2 (5.5 – 23.8) 52.9 20.7/(20 – 100) 32.8* (23.8 – 41.7)
2.9  2.7/(0 – 7) 0.8 (1.3 – 2.8) 6.6  4.0/(0 – 15) 4.5* (2.7 – 6.2)
0.9  1.7/(0 – 5) 0.3 (1.0 – 1.6) 1.5  2.2/(0 – 8) 1.0* (0.0 – 1.9)
1.1 1.9/(0 – 5) 0.3 (1.0 – 1.6) 3.5  2.3/(0 – 7) 2.7* (1.8 – 3.6)
0.9 0.6/(0 – 2) 0.2 (0.3 – 0.7) 1.5  0.8/(0 – 3) 0.8* (0.4 – 1.2)
7.5 2.1/(24 – 30) 0.1 (1.6 – 1.8) 19.2  10.8/(0 – 30) 8.2* (12.2 –4.2)
0 1
1 6
1 6
7 13
7 15
ith an structured interview.
dimensional data; MMSE, Mini Mental State Examination; OR, odds ratio foremb
.
I)
1) 6
6) 5
8)
6)
7) 1
) 4
1
) 2
5)
8) 2
and w
ce forhiatric complications, sleep disturbances, and autonomic
337V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 2 9 – 3 3 8disturbances – that are known to reduce HRQoL, were not con-
sidered. Interestingly, a recent latent variable model study
classified PD patients into four latent classes according to psy-
chiatric and cognitive functioning. Age, disease severity, and
medication use predicted class membership [40]. Further ex-
tensions of this pilot study should assess and include these
influences as well as comorbidities, which are shown to have
an independent negative effect on therapy outcome and
health-related quality-of-life [41,42].
Previous studies that investigated changes in HRQoL over
time in patients with PD using linear models assumed that
individuals follow the same mean trajectory [10,13,43,44].
Conventional methods overlooked individual differences in
changes, regarding them as random error [45]. Longitudinal
studies of PD using observation periods of 2 years and more
have shown deterioration in HRQoL-scores over time
[10,43,44]. Shorter observation periods lead to inconsistent
results [13].
In conclusion, this study provides new information on
the longitudinal development of HRQoL in patients with PD
over a period of 36 months. Different classes or groups were
identified with substantial differences in the evolution of
HRQoL over time. Interestingly, there are groups of patients
whose HRQoL remains stable over longer periods of time.
The classification of HRQoL subgroups may help to explain
the response of PD patients to the natural history of the
disease. Future research is required to identify the potential
responder subgroups in terms of HRQoL on different treat-
ment regimens. This may also allow for more targeted and
systematic PD therapy.
Supplementary Material
Supplementary material associated with this article can be
found, in the online version, at doi:10.1016/j.jval.2010.10.005.
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